Receptor News and Research

RSS

Anti-diabetic medication activates brain sensors, promotes weight gain

Medication used to treat patients with type II diabetes activates sensors on brain cells that increase hunger, causing people taking this drug to gain more body fat, according to researchers at Georgia State University, Oregon Health and Science University, Georgia Regents University and Charlie Norwood Veterans Administration Medical Center.

27 Mar 2015

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research will recognize Philip S. Low, PhD, with the ninth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

26 Mar 2015

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao.

26 Mar 2015

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety.

26 Mar 2015

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate.

25 Mar 2015

Lycera achieves milestone in Merck research collaboration

Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.

25 Mar 2015

New approach to treating B-ALL tumour disease

B cell acute lymphoblastic leukaemia, or B-ALL, is the most common tumour disease in children and also occurs in adults. It develops when signalling pathways in immature B cells, or pre-B cells, are dysregulated. Prof. Dr. Markus Müschen from the University of California in San Francisco, USA, and his team worked together with the BIOSS researchers Prof. Dr. Hassan Jumaa and Prof. Dr. Michael Reth to find a new approach for treating the B-ALL tumour disease.

25 Mar 2015

Early response plus genetic variants strengthen antidepressant outcome prediction

Considering genetic variants in combination with early partial improvement could be useful for predicting antidepressant outcome, say researchers.

24 Mar 2015

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor.

24 Mar 2015

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI).

24 Mar 2015

Keystone meeting focuses on neuroinflammation, Alzheimer's and other neurodegenerative diseases

As Alzheimer's disease sweeps through the brain, do the brain's immune cells sit idly by and let it happen? Or could they overreact and make the disease worse?

23 Mar 2015

Existing drugs could help prevent deadly familial stomach and lobular breast cancers

Deadly familial stomach and lobular breast cancers could be successfully treated at their earliest stages, or even prevented, by existing drugs that have been newly identified by cancer genetics researchers at New Zealand's University of Otago.

23 Mar 2015

New anti-clotting therapy no better than established anticoagulants

A novel therapy that would allow doctors to turn the body's blood-clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing angioplasty but was associated with higher rates of moderate to severe bleeding, according to an analysis of data from a terminated Phase III trial presented at the American College of Cardiology's 64th Annual Scientific Session.

20 Mar 2015

Vitamin D plays major role in preventing diabetes and atherosclerosis

In recent years, a deficiency of vitamin D has been linked to type 2 diabetes and heart disease, two illnesses that commonly occur together and are the most common cause of illness and death in Western countries. Both disorders are rooted in chronic inflammation, which leads to insulin resistance and the buildup of artery-clogging plaque.

19 Mar 2015

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions.

19 Mar 2015

Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, "Cordeliers Research Centre") to obtain unexpected results: drugs used to treat hypertension (high blood pressure) reduce side effects from corticosteroid-based creams used to treat certain skin diseases.

19 Mar 2015

UVA researcher identifies potential therapeutic target for myotonic muscular dystrophy

A doctor who was one of the discoverers of the gene responsible for myotonic muscular dystrophy has now identified a therapeutic that could modify progression of muscle damage and muscle dysfunction associated with the disease - issues that cause patients significant disability and deterioration in quality of life.

19 Mar 2015

Researchers reveal how omega-3 fatty acids inhibit growth of prostate cancer cells

Washington State University researchers have found a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells. The findings, which are at odds with a 2013 study asserting that omega-3s increase the risk of prostate cancer, point the way to more effective anti-cancer drugs.

18 Mar 2015

New study gives glimmer of hope for personalizing treatment for adrenal cancer

A new international study gives a glimmer of hope for personalizing treatment for one of the most rare and aggressive forms of cancer.

18 Mar 2015

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers.

18 Mar 2015

Receptor News and Research

Anti-diabetic medication activates brain sensors, promotes weight gain

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Lycera achieves milestone in Merck research collaboration

New approach to treating B-ALL tumour disease

Early response plus genetic variants strengthen antidepressant outcome prediction

Rigontec raises €4.8 million in second closing of Series A financing round

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Keystone meeting focuses on neuroinflammation, Alzheimer's and other neurodegenerative diseases

Existing drugs could help prevent deadly familial stomach and lobular breast cancers

New anti-clotting therapy no better than established anticoagulants

Vitamin D plays major role in preventing diabetes and atherosclerosis

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

UVA researcher identifies potential therapeutic target for myotonic muscular dystrophy

Researchers reveal how omega-3 fatty acids inhibit growth of prostate cancer cells

New study gives glimmer of hope for personalizing treatment for adrenal cancer

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News